{"entity":{"id":"nct03600233","kind":"trial","name":"Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors","aka":[],"tldr":"A phase 2 trial of CVM-1118 in neuroendocrine tumours and pancreatic ductal adenocarcinoma, run by TaiRx, Inc., active and no longer recruiting.","summary":"Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors is a phase 2 interventional study registered as NCT03600233 by TaiRx, Inc., with 34 participants enrolled, started 2018-12-15 and due to reach its primary completion in 2024-09-30. Interventions recorded: CVM-1118.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03600233","url":"https://clinicaltrials.gov/study/NCT03600233"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["neuroendocrine","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03600233","phase":"2","setting":"A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients With Advanced Neuroendocrine Tumors","sponsor":"TaiRx, Inc.","enrolled":34,"outcomes":[]},"route":"/trials/nct03600233/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}]}}